<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238663</url>
  </required_header>
  <id_info>
    <org_study_id>MB02 A 05 18</org_study_id>
    <nct_id>NCT04238663</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin® and EU Approved Avastin® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare&#xD;
      the pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin®&#xD;
      in healthy male subjects.&#xD;
&#xD;
      During the course of the study, the similarity in pharmacokinetics will be assessed by&#xD;
      sampling the levels of drug in the blood, and by comparing these levels among the different&#xD;
      administration arms. Safety, tolerability, and immunologic response to the administered drugs&#xD;
      will also be evaluated throughout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary PK parameter endpoints are Cmax and AUC(0-∞) for bevacizumab. The secondary PK&#xD;
      endpoints will include all other PK parameters for bevacizumab, including tmax, t1/2, CL and&#xD;
      AUC(0-t).&#xD;
&#xD;
      The serum PK parameters of bevacizumab will be calculated using standard noncompartmental&#xD;
      methods. An analysis of covariance model will be used to analyse the log-transformed primary&#xD;
      PK parameters (AUC[0 ∞] and Cmax) and AUC(0-t). The model will include a fixed effect for&#xD;
      treatment and body weight as a covariate.&#xD;
&#xD;
      All other PK parameters will not be subject to inferential statistical analysis.&#xD;
&#xD;
      Estimates of geometric mean ratios together with the corresponding 90% confidence intervals&#xD;
      (CI) will be derived for the comparisons of the PK parameters as follows:&#xD;
&#xD;
        -  MB02 versus EU Avastin®&#xD;
&#xD;
        -  MB02 versus US Avastin®&#xD;
&#xD;
        -  EU Avastin® versus US Avastin®&#xD;
&#xD;
      PK similarity will be achieved if the 90% CIs for the biosimilar-to-reference ratios of PK&#xD;
      endpoints (AUC[0-∞] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity&#xD;
      criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus&#xD;
      US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®.&#xD;
&#xD;
      All AEs will be listed and summarised using descriptive methodology. All observed, or&#xD;
      patient-reported AEs will be graded by the National Cancer Institute Common Terminology&#xD;
      Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be&#xD;
      presented by severity and by association with the study drugs as determined by the&#xD;
      Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory&#xD;
      Activities. All safety data will be listed and summarised as appropriate.&#xD;
&#xD;
      Immunogenicity data (overall anti-drug antibody [ADA] incidence and titers, and neutralising&#xD;
      ADA results) will be listed. A summary of the number and percent of subjects testing positive&#xD;
      for ADA or neutralising antibodies (NAB) before the dose of MB02, EU Avastin®, or US Avastin®&#xD;
      (Day -1) and at scheduled postdose assessments will be presented by treatment arm. All safety&#xD;
      data and immunogenicity data summaries will be based on the safety analysis population.&#xD;
      Select analyses may be repeated for subsets with or without ADA and de novo ADA formation as&#xD;
      appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Serum Concentration</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC[0-∞]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time of Maximum Observed Serum Concentration</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To evaluate and compare the AUC[0-t] of MB02, US Avastin® and EU Avastin®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL: Total Body Drug Clearance After IV Administration</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To evaluate the CL of MB02, US Avastin® and EU Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Apparent Serum Terminal Elimination Half-life</measure>
    <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
    <description>To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)</measure>
    <time_frame>Day -1, Day 14, Day 28, Day 56, and Day 78</time_frame>
    <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.&#xD;
Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (Safety)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MB02 (Bevacizumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU approved Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US licenced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB02 (Bevacizumab Biosimilar)</intervention_name>
    <description>Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>MB02 (Bevacizumab Biosimilar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU approved Avastin®</intervention_name>
    <description>Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>EU approved Avastin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US licenced Avastin®</intervention_name>
    <description>Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>US licenced Avastin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males of any race, between 18 and 55 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening and Check-in.&#xD;
&#xD;
          3. Total body weight between 60 and 95 kg, inclusive, at Screening and Check-in.&#xD;
&#xD;
          4. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations (congenital nonhaemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is&#xD;
             acceptable) at Screening or Check-in as assessed by the Investigator (or designee).&#xD;
&#xD;
          5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and&#xD;
             clinical chemistry within the following ranges at Screening and Check in. A single&#xD;
             repeat test will be allowed at each timepoint.&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 × 109 L&#xD;
&#xD;
               -  Platelet count ≥100 × 109 L&#xD;
&#xD;
               -  Haemoglobin &gt;10 g/dl&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤1.5 × ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 ULN with direct bilirubin &lt;20% in case of total bilirubin &gt;&#xD;
                  ULN&#xD;
&#xD;
               -  Blood urea nitrogen ≤1.5 × ULN&#xD;
&#xD;
               -  Creatinine &lt;132.63 µmol/L&#xD;
&#xD;
               -  Serum albumin: ≥35 g/L&#xD;
&#xD;
               -  Total cholesterol ≤ 7.75 mmol/L&#xD;
&#xD;
               -  Triglycerides ≤ 3.42 mmol/L&#xD;
&#xD;
               -  Creatine kinase (CK) ≤3 × ULN&#xD;
&#xD;
               -  International normalised ratio (INR) 0.8 to 1.3&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt;2+&#xD;
&#xD;
          6. Systolic blood pressure ≥90 mmHg and &lt;140 mmHg and diastolic blood pressure ≥50 mmHg&#xD;
             and &lt;90 mmHg at Screening and Check in.&#xD;
&#xD;
          7. Subjects agree to use contraception.&#xD;
&#xD;
          8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions. Subjects must have signed an informed consent before any&#xD;
             study-related procedure or evaluation is performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator (or designee).&#xD;
&#xD;
          3. Any current or recent history of active infections, including localised infections.&#xD;
             (Within 2 months prior Screening Visit for any serious infection which requires&#xD;
             hospitalization or intravenous anti-infective, and within 14 days prior Screening&#xD;
             Visit for any active infection which requires oral treatment).&#xD;
&#xD;
          4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence&#xD;
             within 30 days of dosing, or within 30 days of the last study visit.&#xD;
&#xD;
          5. Presence of a nonhealing wound or fracture.&#xD;
&#xD;
          6. Known history of clinically significant essential hypertension, orthostatic&#xD;
             hypotension, fainting spells or blackouts for any reason, cardiac failure or history&#xD;
             of thromboembolic conditions.&#xD;
&#xD;
          7. Medically significant dental disease or dental neglect, with signs and/or symptoms of&#xD;
             local or systemic infection that would likely require a dental procedure during the&#xD;
             course of the study.&#xD;
&#xD;
          8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to&#xD;
             Check-in, and/or positive urinary test for alcohol or drugs of abuse at Screening or&#xD;
             Check in.&#xD;
&#xD;
          9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden&#xD;
             deficiency.&#xD;
&#xD;
         10. History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids&#xD;
             and/or haemoptysis.&#xD;
&#xD;
         11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel&#xD;
             disease, diverticular disease, or any fistulae.&#xD;
&#xD;
         12. Alcohol consumption of &gt;24 units per week. One unit of alcohol equals ½ pint (285 mL)&#xD;
             of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.&#xD;
&#xD;
         13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results&#xD;
             are compatible with prior immunisation and not infection may be included at the&#xD;
             discretion of the Investigator.&#xD;
&#xD;
         14. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of&#xD;
             the investigational drug used in the study.&#xD;
&#xD;
         15. Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
         16. Use or intend use of any prescription medications/ nonprescription products known to&#xD;
             alter drug absorption, metabolism, or elimination processes, including St. John's&#xD;
             wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator&#xD;
             or designee.&#xD;
&#xD;
         17. Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         18. Have received a live or attenuated vaccine from 3 months prior to Screening or have&#xD;
             the intention to receive a vaccine during the study.&#xD;
&#xD;
         19. Intend to travel to a region where a vaccination will be required due to endemic&#xD;
             disease within 3 months of dosing.&#xD;
&#xD;
         20. Previous treatment with an anti VEGF antibody or any other protein or antibody&#xD;
             targeting the VEGF receptor.&#xD;
&#xD;
         21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or&#xD;
             positive cotinine test upon Screening or Check-in.&#xD;
&#xD;
         22. Receipt of blood products within 60 days prior to Check-in.&#xD;
&#xD;
         23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to&#xD;
             Screening, or platelets from 42 days prior to Screening.&#xD;
&#xD;
         24. Poor peripheral venous access.&#xD;
&#xD;
         25. History of abnormal peripheral sensation including paraesthesia and/or numbness in&#xD;
             arms and/or legs.&#xD;
&#xD;
         26. Have previously completed or withdrawn from this study or any other study&#xD;
             investigating bevacizumab, and/or have previously received bevacizumab.&#xD;
&#xD;
         27. Subjects who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
&#xD;
         28. Vulnerable subjects (e.g. persons kept in detention).&#xD;
&#xD;
         29. Subjects who are study site employees or immediate family members of a study site or&#xD;
             Mabxience employee.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male subjects may be enrolled</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Sinn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Early Phase Clinical Unit (EPCU) PAREXEL International GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Early Phase Clinical Unit (EPCU) PAREXEL International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04238663/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04238663/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject in the US Avastin arm withdrew before receiving any study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="P2">
          <title>EU Approved Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="P3">
          <title>US Licenced Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="B2">
          <title>EU Approved Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="B3">
          <title>US Licenced Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="10.18"/>
                    <measurement group_id="B2" value="41.6" spread="11.10"/>
                    <measurement group_id="B3" value="38.3" spread="9.64"/>
                    <measurement group_id="B4" value="39.8" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.48" spread="2.723"/>
                    <measurement group_id="B2" value="24.59" spread="2.322"/>
                    <measurement group_id="B3" value="24.80" spread="2.712"/>
                    <measurement group_id="B4" value="24.62" spread="2.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Serum Concentration</title>
        <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Serum Concentration</title>
          <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
          <units>(ng/mL)/(mg/mL)</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86100" spread="24.8"/>
                    <measurement group_id="O2" value="81100" spread="20.0"/>
                    <measurement group_id="O3" value="87500" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (Cmax) falls completely within the range 0.80-1.25.&#xD;
The PK parameter Cmax was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.976</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>For the comparison, MB02 represents the numerator and EU Avastin represents the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparison, MB02 represents the numerator and US Avastin represents the denominator.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (Cmax) falls completely within the range 0.80-1.25.&#xD;
The PK parameter Cmax was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>0.983</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.897</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (Cmax) falls completely within the range 0.80-1.25.&#xD;
The PK parameter Cmax was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Square Mean</param_type>
            <param_value>0.926</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.851</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>For Ratio of geometric least square mean (GLSM): EU is the numerator and US Avastin acts as the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity</title>
        <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC[0-∞]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity</title>
          <description>To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC[0-∞]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.</description>
          <units>ng*h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30700000" spread="16.2"/>
                    <measurement group_id="O2" value="28800000" spread="16.4"/>
                    <measurement group_id="O3" value="30700000" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 0.80-1.25.&#xD;
The PK parameter AUC[0-∞] was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>For the comparison, MB02 represents the numerator and EU Avastin represents the denominator</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 0.80-1.25.&#xD;
The PK parameter AUC[0-∞] was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>0.998</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.944</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>For the comparison, MB02 represents the numerator and US Avastin represents the denominator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 0.80-1.25.&#xD;
The PK parameter AUC[0-∞] was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>0.934</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.884</ci_lower_limit>
            <ci_upper_limit>0.988</ci_upper_limit>
            <estimate_desc>EU Avastin corresponds to the numerator and US Avastin corresponds to the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time of Maximum Observed Serum Concentration</title>
        <description>To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time of Maximum Observed Serum Concentration</title>
          <description>To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.5" upper_limit="8.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.5" upper_limit="11.9"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.5" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.</title>
        <description>To evaluate and compare the AUC[0-t] of MB02, US Avastin® and EU Avastin®.</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.</title>
          <description>To evaluate and compare the AUC[0-t] of MB02, US Avastin® and EU Avastin®.</description>
          <units>ng*h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29900000" spread="15.6"/>
                    <measurement group_id="O2" value="27900000" spread="16.0"/>
                    <measurement group_id="O3" value="29900000" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL: Total Body Drug Clearance After IV Administration</title>
        <description>To evaluate the CL of MB02, US Avastin® and EU Avastin®</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>CL: Total Body Drug Clearance After IV Administration</title>
          <description>To evaluate the CL of MB02, US Avastin® and EU Avastin®</description>
          <units>l/hour</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00770" spread="18.1"/>
                    <measurement group_id="O2" value="0.00823" spread="18.5"/>
                    <measurement group_id="O3" value="0.00766" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2: Apparent Serum Terminal Elimination Half-life</title>
        <description>To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®</description>
        <time_frame>Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2: Apparent Serum Terminal Elimination Half-life</title>
          <description>To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®</description>
          <units>hours</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="16.9"/>
                    <measurement group_id="O2" value="444" spread="14.5"/>
                    <measurement group_id="O3" value="458" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)</title>
        <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.&#xD;
Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.</description>
        <time_frame>Day -1, Day 14, Day 28, Day 56, and Day 78</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)</title>
          <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.&#xD;
Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAb positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (Safety)</title>
        <description>Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
        <time_frame>Day 1 - Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
          <group group_id="O3">
            <title>US Licenced Avastin®</title>
            <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (Safety)</title>
          <description>Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects discontinued due to TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of mild severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of moderate severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of severe severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration (Day 1 - Day 100)</time_frame>
      <desc>Coded according to Medical Dictionary for Regulatory Activities (version 22.0), and graded on the basis of the US National Cancer Institute's Common Terminology for Adverse Events (version 5.0).&#xD;
Following a request from the Medicines and Healthcare products Regulatory Authority (MHRA) all serious adverse reactions were considered unexpected and reported as SUSARs, for the purpose of safety reporting in healthy volunteers.</desc>
      <group_list>
        <group group_id="E1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="E2">
          <title>EU Approved Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
        <group group_id="E3">
          <title>US Licenced Avastin®</title>
          <description>Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susana Millan</name_or_title>
      <organization>mAbxience Research SL</organization>
      <phone>+34917711500</phone>
      <email>susana.millan@mabxience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

